

NASHVILLE, TN
October 1-3, 2018
Hutton Hotel
A SUMMIT TO CONNECT THE DATA AND DIGITAL INFRASTRUCTURE NEEDED TO ENABLE PRECISION MEDICINE AT SCALE
Stakeholders across the healthcare system face significant barriers to the effective implementation of precision medicine.
Solutions must carefully consider the practical realities of a complex, multi-stakeholder environment.
This Summit provides influential leaders a candid, collaborative forum to define and implement solutions that connect the genetic health information network.

An intimate meeting of influential leaders from across in the Genetic Health Information Network
Representing all stakeholders in this ecosystem, including
- Health plans
- Clinicians
- Hospital systems
- Researchers
- Policy makers
- Patients & Advocates
- Laboratories
- IT Vendors
- Pharma
2018 Organizing Committee
Alphabetical order
Gil Alterovitz, PhD
Director, Biomedical Cybernetics Laboratory
Harvard Medical School
Kristine Bordenave, MD
Corporate Medical Director
Humana
Carlos Bustamante, PhD
Chair, Department of Biomedical Data Science
Stanford University
Joshua Denny, MD
Professor of Biomedical Informatics and Medicine
Vanderbilt University
Henry Garlich
Director, Healthcare Value Solutions & Enhanced Clinical Programs
Blue Shield of California
Trent Haywood, MD, JD
SVP & Chief Medical Officer
Blue Cross Blue Shield Association
Gillian Hooker, PhD, ScM, LCGC
VP, Clinical Development
Concert Genetics
Howard Levy, MD, PhD
Associate Professor of Medicine
Johns Hopkins Medicine
Matt Might, PHD
Director, Hugh Kaul Personalized Medicine Institute
University of Alabama at Birmingham
Robert Nussbaum, MD
Chief Medical Officer
Invitae
Julie Ramage
National Accounts Director, Diagnostics
Pfizer
Benjamin Solomon, MD
Managing Director
GeneDx
The only multi-stakeholder gathering focused on solving the data, digital infrastructure, and economic challenges facing precision medicine
Intimate, carefully curated, invitation-only gathering
Full spectrum of stakeholders
Focused on needs and solutions
Collaborative, discussion-oriented format
Chatham-house rules — non-attribution
No sponsored talks, sales pitches or marketing lists
Published conference summary and recommendations
Identify and resolve practical barriers facing precision medicine by
- Improving the capture of clinical effectiveness and economic value data
- Simplifying the test ordering and resulting workflow for clinicians, hospitals and labs
- Streamlining the genetic test billing, adjudication and payment process
- Reducing the frequency of misordered tests and surprise bills for patients
- Empowering patients to harness the insights in their genetic makeup for greater health

Trent Haywood, MD, JD
SVP & Chief Medical Officer
Blue Cross Blue Shield Association

Robert Nussbaum, MD
Chief Medical Officer
Invitae

Laurie McGraw
SVP, Health Solutions
American Medical Association

Carlos Bustamante, PhD
Chair, Department of Biomedical Data Science
Stanford University

Victoria Pratt, PhD
President-elect
Association for Molecular Pathology

Howard Levy, MD, PhD
Associate Professor of Medicine
Johns Hopkins Medicine

Dawn Barry
Co-Founder and President
Luna DNA

Eli Casdin
Chief Investment Officer
Casdin Capital

Ellen Matloff, MS, CGC
President & CEO
My Gene Counsel

Julie Eggington, MS, PhD
Co-Founder & CEO
Center for Genomic Interpretation

Alex De Winter
Managing Director
GE Ventures

Emily Edelman, MS, CGC
Associate Director of Clinical & Continuing Education
The Jackson Laboratory

Henry Garlich
Director, Healthcare Value Solutions & Enhanced Clinical Programs
Blue Shield of California

Matt Might, PhD
Director, Hugh Kaul Personalized Medicine Institute
University of Alabama at Birmingham

Nick Naclerio, PhD
Founding Partner
Illumina Ventures

James O’Leary
Chief Innovation Officer
Genetic Alliance

Kathryn Lang, MD
Global Medical Strategy Head of Data Science
Pfizer

Bryce Olson
Global Marketing Director, Health and Life Sciences
Intel

Kristine Bordenave, MD
Corporate Medical Director
Humana
+78 Net Promoter Score
This Summit is back by popular demand thanks to the enthusiastic response of last year’s participants.